Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
about
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for the long term treatment of venous thromboembolism in patients with cancerVenous thromboembolic diseaseAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsAnticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the ArtAnticoagulants in cancerEndovascular Interventions for Acute and Chronic Lower Extremity Deep Venous Disease: State of the ArtRisk of venous thromboembolism in patients with cancer: a systematic review and meta-analysisWhat is the Best Treatment for a Cancer Patient with Thrombosis?Management of venous thromboembolism: an updateGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentUnresolved issues in anticoagulant therapyTrousseau's syndrome: multiple definitions and multiple mechanismsSupportive management of patients with brain tumors.Safety of low molecular weight heparins in the treatment of venous thromboembolism.Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.Latest medical treatment strategies for venous thromboembolism.The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewRationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma.Treating venous thromboembolism in patients with cancer.Venous access catheter-related thrombosis in patients with cancer.[Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins].Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study.Venous thromboembolism in cancer patients.Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia.The Treatment of Venous Thromboembolism in Patients with Cancer.Controversies in the management of cancer-associated thrombosis.Cancer and Venous Thromboembolic Disease: A Review.Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalVenous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.Evidence-based guidance on venous thromboembolism in patients with solid tumoursVitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? A qualitative study.Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.
P2860
Q24194904-8EE5586D-FA8B-4107-8840-03B6FAAC8568Q24236620-D1AE8047-CE0A-47B8-8DCB-0487A87991F4Q24243286-AA0165C7-B33E-44AE-9F62-B03B55390361Q24631121-812CAD6B-96F5-41D1-9621-315A894482CBQ24633053-7D62C46D-F358-4C18-B71A-0FB9DE6E266EQ26741697-048DBFCD-94D2-4BD0-9D8D-167CB32AAB18Q26776112-9BE12D06-310D-4607-BC4C-266B55B02DD6Q26825228-F911C4EC-A073-49D1-A856-6BEEB5E617DDQ26864863-1D2DB42C-203B-4578-8E1F-A320D9C21056Q27005043-67C4F437-050B-4A84-8CE7-59B39A502F61Q27009514-66C8782E-1C31-4CD4-8F27-58460B6930FCQ28071443-4BDE1866-826A-41EB-AAAA-CDB033945EB8Q28076077-681DEBF2-2796-4FB8-9F3A-A1D4AAFD74BFQ28196778-F36E534F-33E2-4429-B619-143FEF60205EQ28301882-F61ED4F5-6AE9-412C-B0E1-95A947907543Q30444752-2FF1F302-40AA-432E-BF44-B3AEAA81390AQ33349368-F99000B9-8D09-4E7B-91E2-EA552AE46925Q33362095-BE4F76D4-BAEE-493E-B8CE-8479808BAD63Q33375535-E793A216-2306-462B-B18E-39718319775EQ33376620-6BB34E9D-2D50-4B74-B5D9-639B7AF07BEFQ33380411-4D38F427-D7B6-476B-B976-33B748CBD14BQ33389637-DD3E9FCE-DC2F-4326-890C-CB289672A185Q33393653-EDBB7A81-5E62-4DEE-8EEF-24F6B4924680Q33400564-58D3E750-2ADA-49D2-8300-37505A93CD27Q33408419-C76947C1-6161-4A6F-A94A-CA9E5DE8A6EAQ33413690-9289FFBE-827F-4B8A-8BBA-01075D91EB53Q33417504-37EDCD1A-2951-46A9-AA9A-3BD6E1397EDBQ33419213-725C0E9E-EAFA-4AC2-8DB4-DF35E7A2DDCFQ33422300-F875D26D-D8B6-493F-B6D3-EA8FCBD73EEDQ33434346-A046EC02-ED70-456E-85A1-5B72767D0CF3Q33435329-56EF6CD1-70ED-4EF7-8197-3F6FEA02856CQ33436975-C637F81B-34FB-4495-93F4-F9DF45EB594FQ33439089-E0C35479-DD78-450E-8AAD-236D5A1FBE90Q33561203-CF09737F-4F61-4C9E-AEBF-A5C77E096432Q33561213-76A77335-A80E-4C14-BB64-82EFB899E672Q33763866-4A521944-8D4F-42C3-88EC-278AA9FE4D95Q33763946-6D1D8562-CBA7-47A6-8735-E5A1580CE730Q34062340-2534A253-F79F-44FC-9657-E93838A54076Q34346557-DDAABC3C-0A2D-40BC-AE1C-89DF8CC913C1Q34419638-525949DE-E996-4FA3-9E5E-571C9D946690
P2860
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Comparison of low-molecular-we ...... a randomized controlled study.
@en
Comparison of low-molecular-we ...... a randomized controlled study.
@nl
type
label
Comparison of low-molecular-we ...... a randomized controlled study.
@en
Comparison of low-molecular-we ...... a randomized controlled study.
@nl
prefLabel
Comparison of low-molecular-we ...... a randomized controlled study.
@en
Comparison of low-molecular-we ...... a randomized controlled study.
@nl
P2093
P1476
Comparison of low-molecular-we ...... a randomized controlled study.
@en
P2093
Bernard Lorcerie
Christine Le Maignan
Dominique Farge
Jean Marc Extra
Judith Valcke
Paul Cottu
Philippe Solal-Celigny
Yves Gruel
Zora Marjanovic
P304
P356
10.1001/ARCHINTE.162.15.1729
P407
P577
2002-08-01T00:00:00Z